Literature DB >> 7195773

Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis.

A Gouyette, R Lemoine, J P Adhemar, D Kleinknecht, N K Man, J P Droz, J P Macquet.   

Abstract

After in vitro tests, a tracer dose of cisplatin was administered to an anuric cancer patient. Plasma total platinum levels were monitored as a function of time, as was filterable platinum elimination by hemofiltration dialysis. Based on the derived pharmacokinetic parameters, the patient was later given 50-mg doses of cisplatin, once as a single agent, then four times in combination with doxorubicin, VM-26, and cyclophosphamide. Plasma levels could be fitted by a sum of three exponentials after the infusion was stopped. The mean corresponding half-lives are 30 minutes, 6 hours, and 5 days. Depending on the rate of infusion, plasma peaks ranged between 1.1 micrograms/ml (5.7 X 10(-6) M) and 2.27 micrograms/ml (1.16 X 10(-5) M). During the hemofiltration process immediately following the infusion, the elimination rate was first-order, with a mean half-life of 60 minutes. The mean amount eliminated during the first hemofiltration session was 8% of the dose, decreasing to about 3% on Days 2 and 3. A partial tumor response was observed after two treatment courses, evidenced by the relief of abdominal pain and bowel obstruction episodes and a 50% decrease in peritoneal metastases.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7195773

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

Review 1.  Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.

Authors:  Masatoshi Tomita; Yoichi Aoki; Kenichi Tanaka
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Dose adjustment of carboplatin in patients on hemodialysis.

Authors:  Achuta K Guddati; Parijat S Joy; Creticus P Marak
Journal:  Med Oncol       Date:  2014-01-23       Impact factor: 3.064

Review 3.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

Review 4.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

5.  Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency.

Authors:  R J Motzer; D Niedzwiecki; M Isaacs; C Menendez-Botet; W P Tong; C Flombaum; H I Scher; G J Bosl
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Cisplatin pharmacokinetics in a child receiving peritoneal dialysis.

Authors:  Judit Sebestyen; Uttam Garg; Karen B Lewing; Bradley A Warady; Susan Abdel-Rahman; Douglas L Blowey
Journal:  Pediatr Nephrol       Date:  2010-01-19       Impact factor: 3.714

7.  Extracorporeal Removal of Thermosensitive Liposomal Doxorubicin from Systemic Circulation after Tumor Delivery to Reduce Toxicities.

Authors:  Anjan Motamarry; A Marissa Wolfe; Krishna K Ramajayam; Sanket Pattanaik; Thomas Benton; Yuri Peterson; Pegah Faridi; Punit Prakash; Katherine Twombley; Dieter Haemmerich
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.